Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424
Waks AG, Winer EP (2019) Breast cancer treatment: a review. JAMA 321(3):288–300
CAS PubMed Article Google Scholar
Kramer S, Darsow M, Kummel S, Kimmig R, Rezai M (2008) Breast-conserving treatment of breast cancer–oncological and reconstructive aspects. Gynakol Geburtshilfliche Rundsch 48(2):56–62
Schwartz GF, Veronesi U, Clough KB, Dixon JM, Fentiman IS, Heywang-Kobrunner SH, Holland R, Hughes KS, Mansel RE (2006) Margolese R and others Consensus conference on breast conservation. J Am Coll Surg 203(2):198–207
Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347(16):1233–1241
Kreike B, Hart AA, van de Velde T, Borger J, Peterse H, Rutgers E, Bartelink H, van de Vijver MJ (2008) Continuing risk of ipsilateral breast relapse after breast-conserving therapy at long-term follow-up. Int J Radiat Oncol Biol Phys 71(4):1014–1021
Komoike Y, Akiyama F, Iino Y, Ikeda T, Akashi-Tanaka S, Ohsumi S, Kusama M, Sano M, Shin E, Suemasu K et al (2006) Ipsilateral breast tumor recurrence IBTR after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases. Cancer 106(1):35–41
Nottage MK, Kopciuk KA, Tzontcheva A, Andrulis IL, Bull SB, Blackstein ME (2006) Analysis of incidence and prognostic factors for ipsilateral breast tumour recurrence and its impact on disease-specific survival of women with node-negative breast cancer: a prospective cohort study. Breast Cancer Res 8(4):R44
PubMed PubMed Central Article Google Scholar
Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C, Di Palma S, Simony-Lafontaine J, de Mascarel I, van de Vijver MJ (2001) Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 19(8):2263–2271
CAS PubMed Article Google Scholar
Park CC, Mitsumori M, Nixon A, Recht A, Connolly J, Gelman R, Silver B, Hetelekidis S, Abner A, Harris JR et al (2000) Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. J Clin Oncol 18(8):1668–75
Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, Godwin J, Gray R, Hicks C, James S et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087–106
CAS PubMed Article Google Scholar
Brouwer de Koning SG, VranckenPeeters M, Jozwiak K, Bhairosing PA, Ruers TJM (2018) Tumor resection margin definitions in breast-conserving surgery: systematic review and meta-analysis of the current literature. Clin Breast Cancer 18(4):e595–e600
Chagpar AB, Killelea BK, Tsangaris TN, Butler M, Stavris K, Li F, Yao X, Bossuyt V, Harigopal M, Lannin DR et al (2015) A randomized, controlled trial of cavity shave margins in breast cancer. N Engl J Med 373(6):503–10
CAS PubMed PubMed Central Article Google Scholar
McCahill LE, Single RM, Aiello Bowles EJ, Feigelson HS, James TA, Barney T, Engel JM, Onitilo AA (2012) Variability in reexcision following breast conservation surgery. JAMA 307(5):467–475
Pleijhuis RG, Graafland M, de Vries J, Bart J, de Jong JS, van Dam GM (2009) Obtaining adequate surgical margins in breast-conserving therapy for patients with early-stage breast cancer: current modalities and future directions. Ann Surg Oncol 16(10):2717–2730
PubMed PubMed Central Article Google Scholar
Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, Schinagl D, Oei B, Rodenhuis C, Horiot JC et al (2015) Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol 16(1):47–56
Grant Y, Al-Khudairi R, St John E, Barschkett M, Cunningham D, Al-Mufti R, Hogben K, Thiruchelvam P, Hadjiminas DJ, Darzi A et al (2019) Patient-level costs in margin re-excision for breast-conserving surgery. Br J Surg 106(4):384–394
CAS PubMed Article Google Scholar
Vos EL, Siesling S, Baaijens MHA, Verhoef C, Jager A, Voogd AC, Koppert LB (2017) Omitting re-excision for focally positive margins after breast-conserving surgery does not impair disease-free and overall survival. Breast Cancer Res Treat 164(1):157–167
PubMed PubMed Central Article Google Scholar
Maloney BW, McClatchy DM, Pogue BW, Paulsen KD, Wells WA, Barth RJ (2018) Review of methods for intraoperative margin detection for breast conserving surgery. J Biomed Opt 23(10):1–19
Vahrmeijer AL, Hutteman M, van der Vorst JR, van de Velde CJ, Frangioni JV (2013) Image-guided cancer surgery using near-infrared fluorescence. Nat Rev Clin Oncol 10(9):507–518
CAS PubMed PubMed Central Article Google Scholar
Lamberts LE, Koch M, de Jong JS, Adams ALL, Glatz J, Kranendonk MEG, Terwisscha van Scheltinga AGT, Jansen L, de Vries J, Lub-de Hooge MN et al (2017) Tumor-specific uptake of fluorescent bevacizumab-IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study. Clin Cancer Res 23(11):2730–2741
CAS PubMed Article Google Scholar
Voskuil FJ, Vonk J, van der Vegt B, Kruijff S, Ntziachristos V, van der Zaag PJ, Witjes MJH, van Dam GM (2022) Intraoperative imaging in pathology-assisted surgery. Nat Biomed Eng 6(5):503–514
Smith BL, Gadd MA, Lanahan CR, Rai U, Tang R, Rice-Stitt T, Merrill AL, Strasfeld DB, Ferrer JM, Brachtel EF et al (2018) Real-time, intraoperative detection of residual breast cancer in lumpectomy cavity walls using a novel cathepsin-activated fluorescent imaging system. Breast Cancer Res Treat 171(2):413–420
PubMed PubMed Central Article Google Scholar
Tang R, Coopey SB, Specht MC, Lei L, Gadd MA, Hughes KS, Brachtel EF, Smith BL (2015) Lumpectomy specimen margins are not reliable in predicting residual disease in breast conserving surgery. Am J Surg 210(1):93–98
Hernot S, van Manen L, Debie P, Mieog JSD, Vahrmeijer AL (2019) Latest developments in molecular tracers for fluorescence image-guided cancer surgery. Lancet Oncol 20(7):e354–e367
CAS PubMed Article Google Scholar
Tummers QR, Hoogstins CE, Gaarenstroom KN, de Kroon CD, van Poelgeest MI, Vuyk J, Bosse T, Smit VT, van de Velde CJ, Cohen AF et al (2016) Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17. Oncotarget 7(22):32144–55
PubMed PubMed Central Article Google Scholar
Dintzis SM, Hansen S, Harrington KM, Tan LC, Miller DM, Ishak L, Parrish-Novak J, Kittle D, Perry J, Gombotz C et al (2019) Real-time visualization of breast carcinoma in pathology specimens from patients receiving fluorescent tumor-Marking agent tozuleristide. Arch Pathol Lab Med 143(9):1076–1083
CAS PubMed Article Google Scholar
Unkart JT, Chen SL, Wapnir IL, Gonzalez JE, Harootunian A, Wallace AM (2017) Intraoperative tumor detection using a ratiometric activatable fluorescent peptide: a first-in-human phase 1 study. Ann Surg Oncol 24(11):3167–3173
Voskuil FJ, Steinkamp PJ, Zhao T, van der Vegt B, Koller M, Doff JJ, Jayalakshmi Y, Hartung JP, Gao J, Sumer BD et al (2020) Exploiting metabolic acidosis in solid cancers using a tumor-agnostic pH-activatable nanoprobe for fluorescence-guided surgery. Nat Commun 11(1):3257
CAS PubMed PubMed Central Article Google Scholar
Olson OC, Joyce JA (2015) Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat Rev Cancer 15(12):712–729
CAS PubMed Article Google Scholar
Reiser J, Adair B, Reinheckel T (2010) Specialized roles for cysteine cathepsins in health and disease. J Clin Invest 120(10):3421–3431
CAS PubMed PubMed Central Article Google Scholar
Fonovic M, Turk B (2014) Cysteine cathepsins and extracellular matrix degradation. Biochim Biophys Acta 1840(8):2560–2570
CAS PubMed Article Google Scholar
Brix K, Dunkhorst A, Mayer K, Jordans S (2008) Cysteine cathepsins: cellular roadmap to different functions. Biochimie 90(2):194–207
CAS PubMed Article Google Scholar
Vidak E, Javorsek U, Vizovisek M, Turk B (2019) Cysteine cathepsins and their extracellular roles: shaping the microenvironment. Cells 8(3)
Rudensky A, Beers C (2006) Lysosomal cysteine proteases and antigen presentation. Ernst Schering Res Found Workshop 56:81–95
Turk B, Turk D, Turk V (2000) Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta 1477(1–2):98–111
CAS PubMed Article Google Scholar
Goulet B, Baruch A, Moon NS, Poirier M, Sansregret LL, Erickson A, Bogyo M, Nepveu A (2004) A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. Mol Cell 14(2):207–219
CAS PubMed Article Google Scholar
Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S, Lee-Rykaczewski E, Coleman L, Rieman D, Barthlow R et al (1996) Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 271(21):12511–6
CAS PubMed Article Google Scholar
Nakagawa TY, Brissette WH, Lira PD, Griffiths RJ, Petrushova N, Stock J, McNeish JD, Eastman SE, Howard ED, Clarke SR et al (1999) Impaired invariant chain degradation and antigen presentation and dimin
留言 (0)